ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Clinical trials for ALK-POSITIVE NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new ALK-POSITIVE NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for ALK-POSITIVE NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise against tough lung cancer
Disease control Recruiting nowThis study tests a new daily pill called TRI-611 for adults with advanced ALK-positive non-small cell lung cancer (NSCLC) that has not responded to other treatments. The trial has two parts: first, finding the safest dose, and second, seeing how well it shrinks tumors in differen…
Matched conditions: ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: TRIANA Biomedicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New ALK inhibitor NVL-655 enters trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called neladalkib (NVL-655) in people with advanced ALK-positive non-small cell lung cancer and other solid tumors. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks how well it shrinks tumors. Up to 840 participants will be en…
Matched conditions: ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Antidepressant may ease brain fog from lung cancer drug
Symptom relief Recruiting nowThis study tests whether vortioxetine, an antidepressant known to boost thinking skills, can reduce the mental fogginess caused by the lung cancer drug lorlatinib. About 24 adults with advanced ALK-positive lung cancer who are already taking lorlatinib will receive vortioxetine. …
Matched conditions: ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New program aims to ease distress for advanced lung cancer patients
Symptom relief Recruiting nowThis study is testing a new program called POISE for people with stage IV non-small cell lung cancer who are on targeted therapy. The program includes four visits with a specially trained palliative care clinician to help patients cope with uncertainty and manage their cancer. Re…
Matched conditions: ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC